Proc Natl Acad Sci U S A
. 2022 May 17;119(20):e2120976119.
doi: 10.1073/pnas.2120976119. Epub 2022 May 12.
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Jonathan L Torres 1 , Gabriel Ozorowski 1 , Emanuele Andreano 2 , Hejun Liu 1 , Jeffrey Copps 1 , Giulia Piccini 3 , Lorena Donnici 4 , Matteo Conti 4 , Cyril Planchais 5 , Delphine Planas 6 7 , Noemi Manganaro 2 , Elisa Pantano 2 , Ida Paciello 2 , Piero Pileri 2 , Timothée Bruel 6 7 , Emanuele Montomoli 3 8 9 , Hugo Mouquet 5 , Olivier Schwartz 6 7 , Claudia Sala 2 , Raffaele De Francesco 4 10 , Ian A Wilson 1 11 , Rino Rappuoli 2 12 , Andrew B Ward 1
Affiliations
- PMID: 35549549
- DOI: 10.1073/pnas.2120976119
Abstract
SignificanceClinical candidate monoclonal antibody J08 binds the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S-protein independent of known escape mutations and is able to potently neutralize most variants of concern (VoCs). Here, we explore these properties using cell-based assays and structural studies. A relatively small epitope footprint high on the receptor binding domain (RBD) ridge and the ability to bind multiple conformational states of the S-protein contribute to strong neutralization across several variants.
Keywords: SARS-CoV-2; cryoelectron microscopy; monoclonal therapy; neutralizing antibody; variants of concern.